[Chinese expert consensus on the perioperative medication in laser corneal refractive surgery (2024)].

With the increasing incidence of myopia year by year and the continuous progress of various treatment techniques, laser corneal refractive surgery has become one of the important ways to correct refractive errors. The rational drug use in the perioperative period is important for the success of surgery and reduction of complications. In 2019, based on the development of laser corneal refractive surgery in China, experts from the Refractive Surgery Experts Group of Ocular Microcirculation Branch of Chinese Society of Microcirculation and the Ophthalmology Branch in the Chinese Medical Association formed the "Chinese Expert Consensus on the Perioperative Medication in Laser Corneal Refractive Surgery (2019)". To further promote the expansion of new clinical technologies and surgical methods, and to improve surgical efficacy, the Refractive Surgery Experts Group of Ocular Microcirculation Branch of Chinese Society of Microcirculation, according to the latest domestic and foreign research results, has recently updated the consensus after a collective discussion.